Caris Life Sciences Inc
NASDAQ:CAI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Caris Life Sciences Inc
NASDAQ:CAI
|
US |
|
Orange SA
PAR:ORA
|
FR |
|
A
|
Acteos SA
PAR:EOS
|
FR |
|
Compagnie Financiere Richemont SA
SIX:CFR
|
CH |
|
B
|
Bao Viet Securities JSC
VN:BVS
|
VN |
|
K
|
Koh Brothers Group Ltd
SGX:K75
|
SG |
|
H
|
Hydrogene De France SA
PAR:HDF
|
FR |
|
Resol Holdings Co Ltd
TSE:5261
|
JP |
|
Societe Generale SA
PAR:GLE
|
FR |
|
B
|
Beijing Tong Ren Tang Chinese Medicine Co Ltd
HKEX:3613
|
HK |
Caris Life Sciences Inc
Caris Life Sciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Irving, Texas. The company went IPO on 2025-06-18. Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Caris Life Sciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Irving, Texas. The company went IPO on 2025-06-18. Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Record Results: Caris Life Sciences delivered another record quarter, with Q4 revenue up 125% year-over-year to $293 million and strong profitability metrics.
Full-Year Growth: 2025 full-year revenue increased 97%, driven by molecular profiling revenue up 120% to $766.7 million, with case volume up 22%.
Profitability: The company reported positive GAAP net income of $82 million and full-year adjusted EBITDA of $138 million, marking three consecutive quarters of positive EBITDA and free cash flow.
Gross Margin Expansion: GAAP gross margin reached 75% in Q4 (up from 54% a year ago), and 66% for the full year.
Strong Balance Sheet: Cash on hand surpassed $800 million, increasing by $43 million in Q4.
Guidance Raised: 2026 revenue is guided to $1.0–$1.02 billion (23–26% growth), with molecular profiling expected to grow 21–22% and therapy selection volumes up 20%.
Early Detection Pipeline: Interim study results for Caris Detect showed strong sensitivity (63.1% for Stage 1/2), high specificity, and an AUC of 0.90, supporting a planned Q2 2026 launch.
Commercial Investments: Caris is expanding its sales force by 20–25% in 2026 and investing in both sales and R&D, while maintaining a commitment to positive EBITDA and free cash flow.
